Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Rifkin

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Neurorehabilitation|September 28, 2010
A pilot study of functional electrical stimulation cycling in progressive multiple sclerosisJohn N Ratchford, Wendy Shore, Edward R Hammond, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 15, 2022
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysisReshma L Mahtani, Rajesh Belani, Jeffrey Crawford, et al.
International Immunopharmacology|June 16, 2007
Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell productsRakesh K Singh, Michelle L Varney, Cheryl Leutzinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual diseaseJulie M Vose, Graham Sharp, Wing C Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma RegimensRuben Niesvizky, Ian W Flinn, Robert Rifkin, et al.
BMJ Open Quality|February 17, 2018
Strengthening value-based medication management in a free clinic for the uninsured: Quality interventions aimed at reducing costs and enhancing adherenceRobert K Arao, Michelle Y O'Connor, Thomas Barrett, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 20, 2024
The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect<sup>Ⓡ</sup> MM RegistryRafat Abonour, Hans C Lee, Robert Rifkin, et al.
Expert Opinion on Investigational Drugs|April 23, 2026
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myelomaYuxin Liu, Clifton Mo, Shonali Midha, et al.
Future Oncology (London, England)|February 13, 2023
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myelomaBarry Paul, Michaela Liedtke, Jack Khouri, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Neurorehabilitation|September 28, 2010
A pilot study of functional electrical stimulation cycling in progressive multiple sclerosisJohn N Ratchford, Wendy Shore, Edward R Hammond, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 15, 2022
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysisReshma L Mahtani, Rajesh Belani, Jeffrey Crawford, et al.
International Immunopharmacology|June 16, 2007
Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell productsRakesh K Singh, Michelle L Varney, Cheryl Leutzinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual diseaseJulie M Vose, Graham Sharp, Wing C Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma RegimensRuben Niesvizky, Ian W Flinn, Robert Rifkin, et al.
BMJ Open Quality|February 17, 2018
Strengthening value-based medication management in a free clinic for the uninsured: Quality interventions aimed at reducing costs and enhancing adherenceRobert K Arao, Michelle Y O'Connor, Thomas Barrett, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 20, 2024
The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect<sup>Ⓡ</sup> MM RegistryRafat Abonour, Hans C Lee, Robert Rifkin, et al.
Expert Opinion on Investigational Drugs|April 23, 2026
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myelomaYuxin Liu, Clifton Mo, Shonali Midha, et al.
Future Oncology (London, England)|February 13, 2023
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myelomaBarry Paul, Michaela Liedtke, Jack Khouri, et al.
Pageof 3